Core Viewpoint - The article discusses the impending patent expiration of Semaglutide (GLP-1 receptor agonist) in March 2026, which will lead to increased competition from generic drug manufacturers and a potential price war in the weight loss medication market [5][6]. Group 1: Patent Expiration and Market Impact - Semaglutide has gained significant market share in the weight loss drug sector due to its effectiveness in lowering blood sugar and aiding weight loss, with sales exceeding 3.4 billion yuan in the first three quarters of 2025 [8]. - The patent expiration will allow at least ten domestic pharmaceutical companies, including Jiuyuan Gene and Lizhu Group, to launch their own generic versions of Semaglutide, intensifying market competition [6][10]. - Jiuyuan Gene's biosimilar, Jikeqin®, has shown comparable efficacy and safety to the original drug in clinical trials, indicating a strong entry into the market [6]. Group 2: Competitive Landscape - Novo Nordisk, the original manufacturer of Semaglutide, is facing competition not only from generics but also from Eli Lilly's upcoming oral GLP-1RA, Orforglipron, which has demonstrated superior efficacy in clinical trials [9]. - Orforglipron is expected to achieve sales of $11.8 billion by 2032, highlighting the competitive pressure on Semaglutide as new entrants emerge [9]. - In response to competition, Novo Nordisk has announced significant price reductions for Semaglutide in the U.S. and domestic markets, with price cuts ranging from 35% to 50% [8]. Group 3: Future Outlook and Strategies - The article emphasizes the need for original drug manufacturers to accelerate new drug development or consider mergers and acquisitions to fill revenue gaps as generics flood the market [10][11]. - Domestic companies are innovating in drug formulations, with some introducing long-acting versions and even nasal spray formulations of Semaglutide to differentiate themselves [10]. - The market dynamics are shifting towards efficiency and cost-effectiveness, with companies needing to adapt to consumer preferences for quick and affordable access to medications [11].

Core Viewpoint - Jiuyuan Gene (02566) has received acceptance for the listing application of its product, Jikeqin®, by the National Medical Products Administration of China, marking a significant step in the development of its long-acting GLP-1 receptor agonist, semaglutide biosimilar [1] Group 1: Product Development - Jikeqin® is developed as a biosimilar of semaglutide, classified under biological drug registration category 3.3, intended for weight management in obese or overweight populations [1] - The product mimics the physiological effects of endogenous GLP-1 hormone, promoting insulin secretion, inhibiting glucagon release, suppressing appetite, and delaying gastric emptying to improve blood sugar control and facilitate weight management [1] Group 2: Clinical Trials - A Phase III clinical trial has been conducted, featuring a randomized, open-label, positive-controlled, parallel design to assess the clinical equivalence of Jikeqin® in obese subjects [1] - Results from the trial indicate that Jikeqin® demonstrates clinical equivalence to the reference drug in terms of primary efficacy indicators (weight change rate after 44 weeks of treatment) and safety, showcasing good efficacy and tolerability [1] Group 3: Regulatory Milestones - Jikeqin® received the drug clinical trial approval notice from the National Medical Products Administration in January 2024 and completed the enrollment of all subjects for the Phase III clinical study by December 2024 [1] - The application materials for the listing have been submitted to the National Drug Review Center for evaluation [1]

Core Viewpoint - Jiuyuan Gene (02566.HK) has announced that the application for the market launch of its product, Jikeqin®, has been accepted by the National Medical Products Administration of the People's Republic of China [1] Group 1: Product Development - Jikeqin® is a long-acting GLP-1 receptor agonist, a biosimilar to semaglutide, aimed at weight management for obese or overweight individuals [1] - The product is classified under Category 3.3 for biological drug registration and mimics the physiological effects of endogenous GLP-1 hormone [1] Group 2: Mechanism of Action - Jikeqin® promotes insulin secretion, inhibits glucagon release, suppresses appetite, and delays gastric emptying, thereby improving blood glucose control and facilitating weight management [1] Group 3: Clinical Trials - Phase III clinical trials have shown that Jikeqin® demonstrates clinical equivalence in primary efficacy indicators and safety compared to the reference drug [1] - The trials involved a randomized, open-label, positive-controlled, parallel design and were conducted on obese subjects [1] Group 4: Regulatory Milestones - The drug received a clinical trial approval notice from the National Medical Products Administration in January 2024 and completed the enrollment of all Phase III clinical trial subjects by December 2024 [1] - The application for market launch has been submitted to the National Drug Review Center for evaluation [1]